::: MSD China :::

MSD China is proud to welcome Tasly Group as a corporate member. Tasly Group is the first Chinese corporation to join the MSD China corporate family. Tasly’s participation marks a milestone in the history of minority supplier development in China, demonstrating that supplier diversity, practiced by many US-based multinationals for many years, is gradually being accepted and embraced by Chinese corporations. It is vital to note that IBM played a vital role in convincing Tasly to participate in the minority supplier development program.

Tasly was founded in May 1994. It is a well-known Traditional Chinese Medicine (TCM) pharmaceutical enterprise, whose major products include modern TCM, chemical medicine, biological medicine, nutrition products, cosmetics and bottled water.

By the end of 2008, its total assets reached RMB 8.37 billion. By the end of 2006, Tasly had applied for 694 separate intellectual property rights, including 599 patents of invention, and 22 international PCT patents.

In recent years, Tasly's strategy of internationalization has been conducted in full swing; key regional markets have taken shape in Southeast Asia, Europe, North America and Africa. Its major products have been registered in 34 countries and regions, and the Cardiotonic Pill has undergone FDA and EMEA Phase II and Phase III clinical trials. In 2006, Tasly’s overseas branches earned $ 31.58 million in sales, and $ 6.97 million foreign exchange through self-run exports.